{"pmid":32424489,"title":"Data Analysis of Infection Rates Among Exposed Healthcare Workers Could Reveal Effective Prophylactics Against SARS-CoV-2.","text":["Data Analysis of Infection Rates Among Exposed Healthcare Workers Could Reveal Effective Prophylactics Against SARS-CoV-2.","The global crisis provoked by the SARS-CoV-2 pandemic, and the economic and social consequences associated to the essential policies applied to contain it, necessitates the expedited development of therapeutic solutions. It is a priority to produce data both rapidly and accurately in order to identify current therapies that can be repurposed to offer protection from SARS-CoV-2 infection. As healthcare workers are both at high risk for infection and able to be readily diagnosed, they offer a potential wealth of data to be analyzed. A systematic data analysis of exposure and infection rates among healthcare workers could yield patterns identifying common protective factors, such as medications with prophylactic potential against SARS-CoV-2, that can be fast-tracked into available therapies. With results suggesting their activity against other coronaviruses and their widespread adoption, Antiretroviral cocktails could be a promising initial target for such large-scale data analysis approach.","Adv Exp Med Biol","Nunez-Mujica, Guido","Kichuk, Therese","Carrasco-Lopez, Cesar","32424489"],"abstract":["The global crisis provoked by the SARS-CoV-2 pandemic, and the economic and social consequences associated to the essential policies applied to contain it, necessitates the expedited development of therapeutic solutions. It is a priority to produce data both rapidly and accurately in order to identify current therapies that can be repurposed to offer protection from SARS-CoV-2 infection. As healthcare workers are both at high risk for infection and able to be readily diagnosed, they offer a potential wealth of data to be analyzed. A systematic data analysis of exposure and infection rates among healthcare workers could yield patterns identifying common protective factors, such as medications with prophylactic potential against SARS-CoV-2, that can be fast-tracked into available therapies. With results suggesting their activity against other coronaviruses and their widespread adoption, Antiretroviral cocktails could be a promising initial target for such large-scale data analysis approach."],"journal":"Adv Exp Med Biol","authors":["Nunez-Mujica, Guido","Kichuk, Therese","Carrasco-Lopez, Cesar"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424489","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/5584_2020_540","keywords":["antiretroviral","antiviral","covid-19","coronavirus","data science","healthcare","vaccine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1667252837802835969,"score":9.490897,"similar":[{"pmid":32290293,"pmcid":"PMC7177898","title":"A Review of SARS-CoV-2 and the Ongoing Clinical Trials.","text":["A Review of SARS-CoV-2 and the Ongoing Clinical Trials.","The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.","Int J Mol Sci","Tu, Yung-Fang","Chien, Chian-Shiu","Yarmishyn, Aliaksandr A","Lin, Yi-Ying","Luo, Yung-Hung","Lin, Yi-Tsung","Lai, Wei-Yi","Yang, De-Ming","Chou, Shih-Jie","Yang, Yi-Ping","Wang, Mong-Lien","Chiou, Shih-Hwa","32290293"],"abstract":["The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication, and hydroxychloroquine, the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis."],"journal":"Int J Mol Sci","authors":["Tu, Yung-Fang","Chien, Chian-Shiu","Yarmishyn, Aliaksandr A","Lin, Yi-Ying","Luo, Yung-Hung","Lin, Yi-Tsung","Lai, Wei-Yi","Yang, De-Ming","Chou, Shih-Jie","Yang, Yi-Ping","Wang, Mong-Lien","Chiou, Shih-Hwa"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290293","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.3390/ijms21072657","keywords":["ace2","covid-19","sars-cov-2","clinical trials","immunotherapy","pneumonia","replicase","vaccine"],"locations":["Wuhan","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138494351704066,"score":189.87308},{"pmid":32414379,"title":"COVID-19 in Africa: care and protection for frontline healthcare workers.","text":["COVID-19 in Africa: care and protection for frontline healthcare workers.","Medical staff caring for COVID-19 patients face mental stress, physical exhaustion, separation from families, stigma, and the pain of losing patients and colleagues. Many of them have acquired SARS-CoV-2 and some have died. In Africa, where the pandemic is escalating, there are major gaps in response capacity, especially in human resources and protective equipment. We examine these challenges and propose interventions to protect healthcare workers on the continent, drawing on articles identified on Medline (Pubmed) in a search on 24 March 2020. Global jostling means that supplies of personal protective equipment are limited in Africa. Even low-cost interventions such as facemasks for patients with a cough and water supplies for handwashing may be challenging, as is 'physical distancing' in overcrowded primary health care clinics. Without adequate protection, COVID-19 mortality may be high among healthcare workers and their family in Africa given limited critical care beds and difficulties in transporting ill healthcare workers from rural to urban care centres. Much can be done to protect healthcare workers, however. The continent has learnt invaluable lessons from Ebola and HIV control. HIV counselors and community healthcare workers are key resources, and could promote social distancing and related interventions, dispel myths, support healthcare workers, perform symptom screening and trace contacts. Staff motivation and retention may be enhanced through carefully managed risk 'allowances' or compensation. International support with personnel and protective equipment, especially from China, could turn the pandemic's trajectory in Africa around. Telemedicine holds promise as it rationalises human resources and reduces patient contact and thus infection risks. Importantly, healthcare workers, using their authoritative voice, can promote effective COVID-19 policies and prioritization of their safety. Prioritizing healthcare workers for SARS-CoV-2 testing, hospital beds and targeted research, as well as ensuring that public figures and the population acknowledge the commitment of healthcare workers may help to maintain morale. Clearly there are multiple ways that international support and national commitment could help safeguard healthcare workers in Africa, essential for limiting the pandemic's potentially devastating heath, socio-economic and security impacts on the continent.","Global Health","Chersich, Matthew F","Gray, Glenda","Fairlie, Lee","Eichbaum, Quentin","Mayhew, Susannah","Allwood, Brian","English, Rene","Scorgie, Fiona","Luchters, Stanley","Simpson, Greg","Haghighi, Marjan Mosalman","Pham, Minh Duc","Rees, Helen","32414379"],"abstract":["Medical staff caring for COVID-19 patients face mental stress, physical exhaustion, separation from families, stigma, and the pain of losing patients and colleagues. Many of them have acquired SARS-CoV-2 and some have died. In Africa, where the pandemic is escalating, there are major gaps in response capacity, especially in human resources and protective equipment. We examine these challenges and propose interventions to protect healthcare workers on the continent, drawing on articles identified on Medline (Pubmed) in a search on 24 March 2020. Global jostling means that supplies of personal protective equipment are limited in Africa. Even low-cost interventions such as facemasks for patients with a cough and water supplies for handwashing may be challenging, as is 'physical distancing' in overcrowded primary health care clinics. Without adequate protection, COVID-19 mortality may be high among healthcare workers and their family in Africa given limited critical care beds and difficulties in transporting ill healthcare workers from rural to urban care centres. Much can be done to protect healthcare workers, however. The continent has learnt invaluable lessons from Ebola and HIV control. HIV counselors and community healthcare workers are key resources, and could promote social distancing and related interventions, dispel myths, support healthcare workers, perform symptom screening and trace contacts. Staff motivation and retention may be enhanced through carefully managed risk 'allowances' or compensation. International support with personnel and protective equipment, especially from China, could turn the pandemic's trajectory in Africa around. Telemedicine holds promise as it rationalises human resources and reduces patient contact and thus infection risks. Importantly, healthcare workers, using their authoritative voice, can promote effective COVID-19 policies and prioritization of their safety. Prioritizing healthcare workers for SARS-CoV-2 testing, hospital beds and targeted research, as well as ensuring that public figures and the population acknowledge the commitment of healthcare workers may help to maintain morale. Clearly there are multiple ways that international support and national commitment could help safeguard healthcare workers in Africa, essential for limiting the pandemic's potentially devastating heath, socio-economic and security impacts on the continent."],"journal":"Global Health","authors":["Chersich, Matthew F","Gray, Glenda","Fairlie, Lee","Eichbaum, Quentin","Mayhew, Susannah","Allwood, Brian","English, Rene","Scorgie, Fiona","Luchters, Stanley","Simpson, Greg","Haghighi, Marjan Mosalman","Pham, Minh Duc","Rees, Helen"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414379","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s12992-020-00574-3","keywords":["africa","covid-19","healthcare workers","human resources for health","infection control, mental health","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Water"],"topics":["Prevention"],"weight":1,"_version_":1666991242642194432,"score":151.44748},{"pmid":32320059,"title":"Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.","text":["Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism.","The whole world has entered a terrible crisis with a huge and increasing amount of human deaths and economic loss in fighting the pandemic of COVID-19 caused by the novel coronavirus termed SARS-CoV-2. The live pathogen vaccine (LPV) strategy, which originated in ancient China for fighting smallpox, has been applied successfully in the USA military recruits for decades to control acute respiratory diseases caused by types 4 and 7 adenoviruses. This strategy has also been widely employed in veterinary medicine. These facts suggest a fast way out of the current pandemic crisis, namely that SARS-CoV-2 could be directly used as a live vaccine. Beyond the two traditional mechanisms to guarantee the LPV's safety (SARS-CoV-2 is not highly pathogenic; the LPV is inoculated bypassing the respiratory sites of pathology), three novel mechanisms to further ensure the LPV's safety are available (the virus replication is inhibited with early use of an antiviral drug; symptomatic LPV recipients are cured with convalescent plasma; the LPV is inoculated in hot seasons). This LPV strategy has multiple potential advantages over other options, and could reduce greatly the morbidity and mortality as well as economic loss caused by the pandemic. The safety and efficacy of this strategy should be investigated strictly using animal experiments and clinical trials, and even if the experiments and trials all support the strategy, it should be implemented with enough cautiousness. This article is protected by copyright. All rights reserved.","J Med Virol","Chen, Ji-Wang","Chen, Ji-Ming","32320059"],"abstract":["The whole world has entered a terrible crisis with a huge and increasing amount of human deaths and economic loss in fighting the pandemic of COVID-19 caused by the novel coronavirus termed SARS-CoV-2. The live pathogen vaccine (LPV) strategy, which originated in ancient China for fighting smallpox, has been applied successfully in the USA military recruits for decades to control acute respiratory diseases caused by types 4 and 7 adenoviruses. This strategy has also been widely employed in veterinary medicine. These facts suggest a fast way out of the current pandemic crisis, namely that SARS-CoV-2 could be directly used as a live vaccine. Beyond the two traditional mechanisms to guarantee the LPV's safety (SARS-CoV-2 is not highly pathogenic; the LPV is inoculated bypassing the respiratory sites of pathology), three novel mechanisms to further ensure the LPV's safety are available (the virus replication is inhibited with early use of an antiviral drug; symptomatic LPV recipients are cured with convalescent plasma; the LPV is inoculated in hot seasons). This LPV strategy has multiple potential advantages over other options, and could reduce greatly the morbidity and mortality as well as economic loss caused by the pandemic. The safety and efficacy of this strategy should be investigated strictly using animal experiments and clinical trials, and even if the experiments and trials all support the strategy, it should be implemented with enough cautiousness. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chen, Ji-Wang","Chen, Ji-Ming"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320059","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25920","keywords":["antiviral","coronavirus","pandemic","safety","strategy","vaccine"],"locations":["China","USA"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493636575232,"score":147.26805},{"pmid":32302280,"title":"Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","text":["Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective.","West J Emerg Med","Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan","32302280"],"abstract":["As of March 30(th), 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical trial to evaluate for a potential vaccine and the recipients have started to receive the investigational vaccine.(2) We present a brief overview of the potential prophylactic and treatment agents under investigation, some which could be initiated in the ED if proven effective."],"journal":"West J Emerg Med","authors":["Brown, Cortlyn","Noble, Jeanne","Coralic, Zlatan"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302280","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.5811/westjem.2020.3.47328","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1666138494899060736,"score":146.94687},{"pmid":32320327,"title":"Respiratory Protection Considerations for Healthcare Workers During the COVID-19 Pandemic.","text":["Respiratory Protection Considerations for Healthcare Workers During the COVID-19 Pandemic.","The COVID-19 pandemic has resulted in a surge of patients that exceeds available human and physical resources in many settings, triggering the implementation of crisis standards of care. High-quality respiratory protection is essential to reduce exposure among healthcare workers, yet dire shortages of personal protective equipment in the United States threaten the health and safety of this essential workforce. In the context of rapidly changing conditions and incomplete data, this article outlines 3 important strategies to improve healthcare workers' respiratory protection. At a minimum, healthcare workers delivering care to patients with confirmed or suspected COVID-19 should wear N95 respirators and full-face shields. Several mechanisms exist to boost and protect the supply of N95 respirators, including rigorous decontamination protocols, invoking the Defense Production Act, expanded use of reusable elastomeric respirators, and repurposing industrial N95 respirators. Finally, homemade facial coverings do not protect healthcare workers and should be avoided. These strategies, coupled with longer-term strategies of investments in protective equipment research, infrastructure, and data systems, provide a framework to protect healthcare workers immediately and enhance preparedness efforts for future pandemics.","Health Secur","Friese, Christopher R","Veenema, Tener Goodwin","Johnson, James S","Jayaraman, Sundaresan","Chang, James C","Clever, Linda Hawes","32320327"],"abstract":["The COVID-19 pandemic has resulted in a surge of patients that exceeds available human and physical resources in many settings, triggering the implementation of crisis standards of care. High-quality respiratory protection is essential to reduce exposure among healthcare workers, yet dire shortages of personal protective equipment in the United States threaten the health and safety of this essential workforce. In the context of rapidly changing conditions and incomplete data, this article outlines 3 important strategies to improve healthcare workers' respiratory protection. At a minimum, healthcare workers delivering care to patients with confirmed or suspected COVID-19 should wear N95 respirators and full-face shields. Several mechanisms exist to boost and protect the supply of N95 respirators, including rigorous decontamination protocols, invoking the Defense Production Act, expanded use of reusable elastomeric respirators, and repurposing industrial N95 respirators. Finally, homemade facial coverings do not protect healthcare workers and should be avoided. These strategies, coupled with longer-term strategies of investments in protective equipment research, infrastructure, and data systems, provide a framework to protect healthcare workers immediately and enhance preparedness efforts for future pandemics."],"journal":"Health Secur","authors":["Friese, Christopher R","Veenema, Tener Goodwin","Johnson, James S","Jayaraman, Sundaresan","Chang, James C","Clever, Linda Hawes"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320327","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1089/hs.2020.0036","keywords":["covid-19","healthcare workers","personal protective equipment"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138493735141376,"score":143.54514}]}